These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 14640930)

  • 1. Transdermal oxybutynin: a new treatment for overactive bladder.
    Davila GW
    Expert Opin Pharmacother; 2003 Dec; 4(12):2315-24. PubMed ID: 14640930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal drug delivery treatment for overactive bladder.
    Dmochowski RR; Starkman JS; Davila GW
    Int Braz J Urol; 2006; 32(5):513-20. PubMed ID: 17081319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxybutynin topical and transdermal formulations: an update.
    Staskin DR; Salvatore S
    Drugs Today (Barc); 2010 Jun; 46(6):417-25. PubMed ID: 20571610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermally-delivered oxybutynin (Oxytrol(R) for overactive bladder.
    Ho C
    Issues Emerg Health Technol; 2001 Oct; (24):1-4. PubMed ID: 11776281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.
    Abramov Y; Sand PK
    Expert Opin Pharmacother; 2004 Nov; 5(11):2351-9. PubMed ID: 15500382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal oxybutynin.
    Baldwin CM; Keating GM
    Drugs; 2009; 69(3):327-37. PubMed ID: 19275276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.
    Appell RA; Chancellor MB; Zobrist RH; Thomas H; Sanders SW
    Mayo Clin Proc; 2003 Jun; 78(6):696-702. PubMed ID: 12934778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal oxybutynin: for overactive bladder.
    Bang LM; Easthope SE; Perry CM
    Drugs Aging; 2003; 20(11):857-64. PubMed ID: 12964892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
    Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH;
    Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oxybutynin chloride topical gel: effects of application site, baths, sunscreen and person-to-person transference.
    Dmochowski RR; Newman DK; Sand PK; Rudy DC; Caramelli KE; Thomas H; Hoel G
    Clin Drug Investig; 2011; 31(8):559-571. PubMed ID: 21721591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which anticholinergic drug for overactive bladder symptoms in adults.
    Hay-Smith J; Herbison P; Ellis G; Morris A
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005429. PubMed ID: 16034974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
    Saltzstein L
    Urol Nurs; 2005 Aug; 25(4):260-2. PubMed ID: 16225342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder.
    Staskin DR; Robinson D
    Expert Opin Pharmacother; 2009 Dec; 10(18):3103-11. PubMed ID: 19954278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The newer antimuscarinic drugs: bladder control with less dry mouth.
    Appell RA
    Cleve Clin J Med; 2002 Oct; 69(10):761, 765-6, 768-9. PubMed ID: 12371799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
    Sand PK; Goldberg RP; Dmochowski RR; McIlwain M; Dahl NV
    Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.